Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients

Abstract

TCI of landiolol hydrochloride is useful for controlling HR, and the PK parameters of landiolol in gynecologic patients were similar to those in healthy male volunteers and best described by a 2-compartment model with lag time.

Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease

“…In fact, PK parameters of landiolol in low-risk patients and healthy volunteers are similar. 4 The present study revealed that V 1 and CL in patients with PAD decreased approximately 36% and 16%, respectively, compared with the values in healthy volunteers. These findings indicate that the increase of plasma concentration of landiolol hydrochloride in patients with PAD is due to V 1 in the early period of administration and to CL in steady state, when compared with the concentration in healthy volunteers and/or low-risk patients.…”

“…Since the STANPUMP software cannot input lag time (ALAG), we used Honda et al’s parameter 6 without ALAG. It is important to note that this method shifts the predicted plasma concentration curve toward left parallel, 4 although the administration strategy does not change and PK analysis is not affected because the actual history of landiolol administration for PK analysis is used. TCI of landiolol hydrochloride was performed to achieve target plasma concentrations of 500 and 1,000 ng/mL ( Figure 1 ).…”

“…However, whether the efficacy of landiolol is attributable to pharmacokinetics (PK) or pharmacodynamics (PD) is still unknown, because information on the landiolol PK in high-risk patients is lacking. Recently, we determined that PK parameters of landiolol in low-risk gynecological patients are similar to those in healthy volunteers; 4 however, PK parameters in high-risk patients are still unknown. Therefore, in order to address the above question, we designed the present study with the purpose of determining the PK parameters of landiolol in patients with peripheral arterial disease (PAD).…”

Model-based drug administration

“…Patient-controlled analgesia with TCI for hydromorphone infusion for postoperative pain therapy using a recently described new pharmacokinetic model [39] was found to offer satisfactory postoperative pain therapy with moderate side-effects [40 & ]. Outside the field of perioperative medicine, TCI of landiolol hydrochloride, a newly developed cardioselective, ultrashort acting b1-adrenergic receptor blocking agent, was found to be very effective in controlling heart rate (HR) and the pharmacokinetic parameters were best described by a two compartmental pharmacokinetic model [41,42].…”